VB-111
Phase 3Small molecule
VB-111 is one of 149 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.
4
Indications
5
Total Trials
0
Active Trials
148
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Piqray
NovartisPhase 3
Vepesid
AAvyxa
Phase 3
Grafapex
MMedexus Pharma, Inc.
Phase 3
Naropin
FFresenius Kabi Oncology Ltd.
Phase 3
Arimidex
IIstituto Clinico Humanitas
Phase 3
Rina-S
GenmabPhase 3
Karenitecin
BBioNumerik Pharmaceuticals, Inc.
Phase 3
VB-111
VVascular Biogenics Ltd. operating as VBL Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Thyroid Cancer1 trial
Metastatic Cancer1 trial
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
Unknown status·VVascular Biogenics Ltd. operating as VBL Therapeutics·Phase 1·NCT00559117·48 enrolled
Glioblastoma Multiforme1 trial
Glioblastoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VB-111. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details